Hypertension in end-stage renal disease.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use; D044383:Black People; D001794:Blood Pressure; D001835:Body Weight; D002908:Chronic Disease; D003928:Diabetic Nephropathies / Q000150:complications; D004487:Edema / Q000150:complications; D005110:Extracellular Space; D005260:Female; D005921:Glomerulonephritis / Q000150:complications; D006145:Guanethidine / Q000627:therapeutic use; D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use; D006977:Hypertension, Renal / Q000097:blood / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology / Q000601:surgery; D007668:Kidney / Q000032:analysis; D007674:Kidney Diseases / Q000150:complications*; D052177:Kidney Diseases, Cystic / Q000150:complications; D008297:Male; D008750:Methyldopa / Q000627:therapeutic use; D008875:Middle Aged; D009392:Nephrectomy; D009395:Nephritis, Interstitial / Q000150:complications; D010530:Peritoneal Dialysis; D011704:Pyelonephritis / Q000150:complications; D012083:Renin / Q000032:analysis / Q000097:blood; D014882:Water-Electrolyte Balance; D044465:White People
D000959:Antihypertensive Agents; D006830:Hydralazine; D008750:Methyldopa; D012083:Renin; D006145:Guanethidine